These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 14522458)

  • 1. Specific activation of CMV-primed human T lymphocytes by cytomegalovirus pp65 expressed in fission yeast.
    Breinig F; Heintel T; Schumacher A; Meyerhans A; Schmitt MJ
    FEMS Immunol Med Microbiol; 2003 Oct; 38(3):231-9. PubMed ID: 14522458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ex vivo stimulation and expansion of both CD4(+) and CD8(+) T cells from peripheral blood mononuclear cells of human cytomegalovirus-seropositive blood donors by using a soluble recombinant chimeric protein, IE1-pp65.
    Vaz-Santiago J; Lulé J; Rohrlich P; Jacquier C; Gibert N; Le Roy E; Betbeder D; Davignon JL; Davrinche C
    J Virol; 2001 Sep; 75(17):7840-7. PubMed ID: 11483727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a lentiviral vector encoding a HCMV-chimeric IE1-pp65 protein for epitope identification in HLA-Transgenic mice and for ex vivo stimulation and expansion of CD8(+) cytotoxic T cells from human peripheral blood cells.
    Rohrlich PS; Cardinaud S; Lulè J; Montero-Julian FA; Prodhomme V; Firat H; Davignon JL; Perret E; Monseaux S; Necker A; Michelson S; Lemonnier FA; Charneau P; Davrinche C
    Hum Immunol; 2004 May; 65(5):514-22. PubMed ID: 15172452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL.
    Wills MR; Carmichael AJ; Mynard K; Jin X; Weekes MP; Plachter B; Sissons JG
    J Virol; 1996 Nov; 70(11):7569-79. PubMed ID: 8892876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects.
    Berencsi K; Gyulai Z; Gönczöl E; Pincus S; Cox WI; Michelson S; Kari L; Meric C; Cadoz M; Zahradnik J; Starr S; Plotkin S
    J Infect Dis; 2001 Apr; 183(8):1171-9. PubMed ID: 11262198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of HLA-G-restricted human cytomegalovirus pp65 (UL83)-specific cytotoxic T lymphocytes in HLA-G transgenic mice.
    Lenfant F; Pizzato N; Liang S; Davrinche C; Le Bouteiller P; Horuzsko A
    J Gen Virol; 2003 Feb; 84(Pt 2):307-317. PubMed ID: 12560562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term stable expanded human CD4+ T cell clones specific for human cytomegalovirus are distributed in both CD45RAhigh and CD45ROhigh populations.
    Weekes MP; Wills MR; Sissons JG; Carmichael AJ
    J Immunol; 2004 Nov; 173(9):5843-51. PubMed ID: 15494538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous generation of cytomegalovirus-specific CD8+ and CD4+ T lymphocytes by use of dendritic cells comodified with pp65 mRNA and pp65 protein.
    Carlsson B; Hou M; Giandomenico V; Nilsson B; Totterman TH; Essand M
    J Infect Dis; 2005 Dec; 192(11):1912-20. PubMed ID: 16267762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B lymphoblastoid cell lines as efficient APC to elicit CD8+ T cell responses against a cytomegalovirus antigen.
    Sun Q; Burton RL; Dai LJ; Britt WJ; Lucas KG
    J Immunol; 2000 Oct; 165(7):4105-11. PubMed ID: 11034422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of cytomegalovirus-specific human T-lymphocyte clones by using autologous B-lymphoblastoid cells with stable expression of pp65 or IE1 proteins: a tool to study the fine specificity of the antiviral response.
    Retière C; Prod'homme V; Imbert-Marcille BM; Bonneville M; Vié H; Hallet MM
    J Virol; 2000 May; 74(9):3948-52. PubMed ID: 10756006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IE1-pp65 recombinant protein from human CMV combined with a nanoparticulate carrier, SMBV, as a potential source for the development of anti-human CMV adoptive immunotherapy.
    Vaz-Santiago J; Lulé J; Rohrlich P; Kravtzoff R; Le Roy E; Davignon JL; Betbeder D; Davrinche C
    Cytotherapy; 2002; 4(1):11-9. PubMed ID: 11953037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble recombinant CMVpp65 spanning multiple HLA alleles for reconstitution of antiviral CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation.
    Paine A; Oelke M; Tischer S; Heuft HG; Blasczyk R; Eiz-Vesper B
    J Immunother; 2010 Jan; 33(1):60-72. PubMed ID: 19952955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Robust expansion of viral antigen-specific CD4+ and CD8+ T cells for adoptive T cell therapy using gene-modified activated T cells as antigen presenting cells.
    Melenhorst JJ; Solomon SR; Shenoy A; Hensel NF; McCoy JP; Keyvanfar K; Barrett AJ
    J Immunother; 2006; 29(4):436-43; discussion 365-6. PubMed ID: 16799339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of cytotoxic function of CMV-pp65-specific CD8+ T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplants.
    Lacey SF; Gallez-Hawkins G; Crooks M; Martinez J; Senitzer D; Forman SJ; Spielberger R; Zaia JA; Diamond DJ
    Transplantation; 2002 Sep; 74(5):722-32. PubMed ID: 12352893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of gene transfer and antigen-loaded dendritic cells for the generation of CD4+ and CD8+ cytomegalovirus-specific T cells in HLA-A2+ and HLA-A2- donors.
    Foster AE; Bradstock KF; Sili U; Marangolo M; Rooney CM; Gottlieb DJ
    Biol Blood Marrow Transplant; 2004 Nov; 10(11):761-71. PubMed ID: 15505607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid generation of CMV pp65-specific T cells for immunotherapy.
    Bao L; Sun Q; Lucas KG
    J Immunother; 2007; 30(5):557-61. PubMed ID: 17589296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals.
    Kern F; Bunde T; Faulhaber N; Kiecker F; Khatamzas E; Rudawski IM; Pruss A; Gratama JW; Volkmer-Engert R; Ewert R; Reinke P; Volk HD; Picker LJ
    J Infect Dis; 2002 Jun; 185(12):1709-16. PubMed ID: 12085315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incoming human cytomegalovirus pp65 (UL83) contained in apoptotic infected fibroblasts is cross-presented to CD8(+) T cells by dendritic cells.
    Arrode G; Boccaccio C; Lulé J; Allart S; Moinard N; Abastado JP; Alam A; Davrinche C
    J Virol; 2000 Nov; 74(21):10018-24. PubMed ID: 11024130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transfection of dendritic cells with in vitro-transcribed CMV RNA induces polyclonal CD8+- and CD4+-mediated CMV-specific T cell responses.
    Heine A; Grünebach F; Holderried T; Appel S; Weck MM; Dörfel D; Sinzger C; Brossart P
    Mol Ther; 2006 Feb; 13(2):280-8. PubMed ID: 16219490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy maintain activated CD8+ T cell subsets as a strong adaptive immune response to cytomegalovirus.
    Villacres MC; Lacey SF; La Rosa C; Krishnan R; Auge C; Longmate J; Zaia JA; Leedom JM; Diamond DJ
    J Infect Dis; 2001 Aug; 184(3):256-67. PubMed ID: 11443550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.